MLchartDataset catalogue

avotaciclib

Term · Oncology and biomedicine · MLC-T-ONC-011826

An orally bioavailable, cyclin dependent kinase 1 (CDK1) inhibitor, with potential antineoplastic activity. Upon administration, avotaciclib targets, binds to and inhibits the activity of CDK1. This may inhibit cancer stem cell (CSC) division, cause cell cycle arrest, and induce apoptosis. This may inhibit tumor cell proliferation. CDK1, an ATP-dependent serine/threonine kinase, plays a key role in regulating cell division, cell cycle progression and proliferation. It is frequently overexpressed in tumor cells.

Table 1. Record
IdentifierMLC-T-ONC-011826
FieldOncology and biomedicine
SynonymsCDK1 inhibitor BEY1107
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-011826",
  "term": "avotaciclib",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, cyclin dependent kinase 1 (CDK1) inhibitor, with potential antineoplastic activity. Upon administration, avotaciclib targets, binds to and inhibits the activity of CDK1. This may inhibit cancer stem cell (CSC) division, cause cell cycle arrest, and induce apoptosis. This may inhibit tumor cell proliferation. CDK1, an ATP-dependent serine/threonine kinase, plays a key role in regulating cell division, cell cycle progression and proliferation. It is frequently overexpressed in tumor cells.",
  "synonyms": [
    "CDK1 inhibitor BEY1107"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/avotaciclib/"
}

Record 3,182 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.